Innate Pharma (Nasdaq: IPHA) will host an in-person and virtual event on IPH4502 Phase 1 data on November 18, 2026. The event begins at 11:00 a.m. ET / 4:00 p.m. GMT at IET London, Savoy Place.Professor Yohann Loriot of Gustave Roussy will join management to discuss safety, pharmacokinetics—the drug's behavior in the body—and antitumor activity from the dose-escalation study. Presentations will also cover the urothelial cancer treatment landscape and next steps in IPH4502's clinical development, followed by a live question-and-answer session. A replay will be available in the investors section of Innate Pharma's website.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Innate Pharma (IPHA) announced that AstraZeneca now expects the PACIFIC-9 Phase 3 trial’s high-level data readout in H1 2027. The previous expectation was the second half of 2026. The company attributed the revised timing to the study’s event-driven nature.The AstraZeneca-led trial evaluates durvalumab combined with monalizumab or oleclumab in patients with unresectable Stage III non-small cell lung cancer, meaning cancer that cannot be surgically removed. Eligible patients have not progressed following platinum-based chemotherapy and radiation therapy. Enrollment is complete. Monalizumab is an anti-NKG2A antibody developed by Innate Pharma in collaboration with AstraZeneca. AstraZeneca obtained full oncology rights to monalizumab in October 2018 through a co-development and commercialisation agreement initiated in 2015.

Innate Pharma (Nasdaq: IPHA) announced that its executive team members will participate in two healthcare investor conferences in November 2026. The Stifel Healthcare Conference takes place November 10–12 in New York, with a fireside chat on November 10 at 2:00 p.m. ET / 8:00 p.m. CET. A live webcast and subsequent replay will be available through the company’s investor Events page. The Jefferies Global Healthcare Conference runs November 16–19 in London.